Veterinary Regenerative Medicine Market To Reach $3.1 Billion By 2033

Veterinary Regenerative Medicine Market Growth & Trends

The global veterinary regenerative medicine market size is expected to reach USD 3.1 billion by 2033, registering a CAGR of 10.4% from 2026 to 2033, according to a new report by Grand View Research, Inc. The key factors driving the growth include the rising incidence of soft tissue injuries and osteoarthritis in animals, rising pet industry expenditure, expanding access to veterinary services, and several advantages of animal stem cell therapy. Thirty-three percent of training losses and waste in sport horses across all categories are attributable to soft tissue injuries, which can damage any tendon or ligament. These injuries account for 13% to 18% of horses who need rest and time off. An increase in acute workload and fitness level, among other things, are two major factors that contribute to soft tissue injury in horses. 

Animal stem cell therapy has several benefits, further fueling the market’s growth. These days, animal stem cell therapy is very popular due to its capacity to utilize an animal's own stem cells to prolong treatment for a disease or illness. Animals who receive this therapy live much longer. Many health problems, including arthritis, degenerative joint disorders, and ligament and tendon injuries in animals, have seen a large increase in occurrences in recent years. Cats, dogs, and horses are frequently treated with stem cell treatment. This factor is supporting the growth of the market for veterinary regenerative medicine worldwide.

Companies are focusing on animal stem cell therapies to reduce the prevalence of disease in animals and improve the animal's quality of life. Animal stem cell research has tremendous potential for understanding fundamental mechanisms of animal development, as well as for treating a wide range of diseases and disorders in animals. All of these factors work as drivers for the market for veterinary regenerative medicine to grow rapidly. Furthermore, increased investment in R&D activities in the animal stem cell therapy market is one of the primary factors driving the market growth. 

Pet owners are reluctant to spend a sizable number of money on their pet's treatment because animal stem cell therapy is fairly expensive. Also, many conventional veterinary hospitals are not equipped to treat animals with stem cells. Although pet insurance companies pay for stem cell treatments, they do not pay for additional procedures like retreatment. A significant percentage of pet owners do not have pet insurance, which will limit the future growth of the market for animal regenerative medicine.

In veterinary medicine, regenerative therapies such as mesenchymal stem cells, platelet-rich plasma, and autologous serum products are becoming increasingly popular for treating horses and dogs. The main objectives of regenerative therapies are to control immune responses, stop the immune system from causing additional tissue damage, and administer trophic and growth hormones to promote endogenous tissue regeneration. The FDA has not yet approved any cell-based regenerative medicines.

A lack of standardization in the tissue origin, the timing of injection, dosing, and use of adjunct therapies may be the cause of the lack of agreement on treatment protocols for MSC therapy in veterinary medicine, which may account for variations in treatment efficacy reported for different clinical trials. For the treatment of tendinitis, osteoarthritis, and desmitis, MSC therapy has the most clinical evidence of clinical efficacy. When tendon injuries are treated with MSCs in horses and dogs, the tissue composition and fiber alignment are improved, and the recurrence rates are reduced.

 Request a free sample copy or view report summary: Veterinary Regenerative Medicine Market Report

Veterinary Regenerative Medicine Market Report Highlights

• The small animals segment accounted for the largest market revenue share in 2025 and is projected to grow at the fastest CAGR during the forecast period. Rising pet ownership, increased spending on advanced treatments, and growing awareness of regenerative therapies are driving demand.

• The stem cells segment accounted for the largest market revenue share in 2025, driven by their ability to repair, regenerate, and restore damaged tissues in companion and large animals.

• The orthopedics segment led the market with the largest revenue share of 41.8% in 2025, driven by the high prevalence of musculoskeletal disorders such as osteoarthritis, ligament injuries, and joint degeneration in companion and performance animals.

• The veterinary hospitals and clinics segment accounted for the largest market share in 2025, serving as primary hubs for administering advanced therapies, including stem cell treatments, PRP, and tissue engineering solutions.

• North America dominated the global veterinary regenerative medicine market with the largest revenue share of 37.3% in 2025, driven by rising pet ownership, increasing prevalence of osteoarthritis, and demand for minimally invasive treatments.

Veterinary Regenerative Medicine Market Segmentation

Grand View Research has segmented the global veterinary regenerative medicine market based on animal, product, application, end use, and region:

Veterinary Regenerative Medicine Animal Outlook (Revenue, USD Million, 2021 - 2033)

• Small Animals

• Large Animals

Veterinary Regenerative Medicine Product Outlook (Revenue, USD Million, 2021 - 2033)

• Stem Cells

• Platelet-Rich Plasma

• Others

Veterinary Regenerative Medicine Application Outlook (Revenue, USD Million, 2021 - 2033)

• Orthopedics

• Trauma/Wound Care

• Others

Veterinary Regenerative Medicine End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Veterinary Hospitals/Clinics

• Veterinary Research Institutes

Veterinary Regenerative Medicine Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • India

  • China

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

  • Qatar

  • Oman

List Of Key Players Veterinary Regenerative Medicine Market

• Boehringer Ingelheim International GmbH

• Zoetis Services LLC

• Dechra

• Integra Lifesciences

• Vetherapy

• Vetstem, Inc.

• Ardent

• Enso Discoveries

• Animal Cell Therapies, Inc.

• Vetbiologics

• Medrego

• Celavet Inc